DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer

Breast Cancer Metastatic Clinical Trial

Official title:

A Phase I, Open-Label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of DZD1516 in Combination With Trastuzumab and Capecitabine, or DZD1516 in Combination With T-DM1, in Patients With Metastatic HER2 Positive (HER2+) Breast Cancer

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04509596
• Other study ID #: DZ2019HE001
• Status: Active, not recruiting
• Phase: Phase 1
• Start date: September 21, 2020
• Est. completion date: May 2024

Study information

• Verified date: September 2023
• Source: Dizal Pharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

DZD1516 is an oral, blood brain barrier penetrable, selective HER2 tyrosine kinase inhibitor. This study is designed to evaluate the safety and tolerability of DZD1516 in patients with metastatic HER2 positive breast cancer who have progressed following prior therapy. This is the first time this drug has ever been tested in patients, and so it will help to understand what type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body and assess its anti-cancer activity as monotherapy and in combination with trastuzumab and/or capecitabine, or in combination with T-DM1

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 23
• Est. completion date: May 2024
• Est. primary completion date: January 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Signed informed consent.

• Male or female patients aged = 18 years

• histologically or cytologically confirmed HER2 positive advanced breast cancer which failed prior therapies

• Predicted life expectancy = 12 weeks.

• ECOG performance status 0 to 1 for patients without LM, and 0 to 2 for patients with LM at the time of signing ICF

• Adequate bone marrow reserve and organ system functions

• For patients without CNS metastases, patients must have at least one measurable lesion according to RECIST (version 1.1)

• For patients with Brain metastasis: Patient must have at least one measurable intracranial lesion according to modified RECIST 1.1

Exclusion Criteria:

• Intervention with any of the following: Any investigational agents or study drugs from a previous clinical study within 4 weeks of the first dose of study treatment; Any cytotoxic chemotherapy or other anticancer drugs for the treatment of metastatic breast cancer from a previous treatment regimen within 4 weeks of the first dose of study treatment; Any intrathecal chemotherapy within 2 weeks of the first dose of study treatment;Major surgery procedure (excluding placement of vascular access), or significant traumatic injury within 4 weeks of the first dose of study treatment, or have an anticipated need for major surgery during the study; Radiotherapy with a wide field of radiation within 4 weeks or radiotherapy with a limited field of radiation for palliation within 1 week of the first dose of study treatment;

• CNS complications that require urgent neurosurgical intervention

• Any evidence of severe or uncontrolled systemic diseases

• Another malignancy within 5 years prior to enrolment with the exception of adequately treated in-situ carcinoma of the cervix, uterus, basal or squamous cell carcinoma or non-melanomatous skin cancer.

• Live vaccines within 4 weeks prior to first dose.

• Active infections including:Tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and tuberculosis testing in line with local practice);Positive Hepatitis B surface antigen (HBsAg) or positive HCV antibodies or confirmed positive HIV test result.

• Refractory nausea and vomiting if not controlled by supportive therapy, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of DZD1516

• Involvement in the planning and conduct of the study (applies to Sponsor staff or staff at the study site).

• Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements.

Related Conditions & MeSH terms

• Breast Cancer Metastatic
• Breast Neoplasms

Intervention

Drug:
• DZD1516 mono therapy in Part A, DZD1516 in combination with trastuzumab and/or capecitabine in Part B, DZD1516 in combination with T-DM1 in Part C
Part A is twice daily (except Cycle 0) oral dosing of DZD1516, starting from 50 mg. If tolerated, dose will be escalated in subsequent cohorts until MTD. Part B is twice daily oral dosing of DZD1516 in combination with capecitabine 1000 mg/m2 orally twice daily on Days 1-14 of each 21-day cycle or with trastuzumab 8 mg/kg intravenously (IV) on Day 1 of Cycle 1, followed by 6 mg/kg on Day 1 of each 21-day cycle. Part C is twice daily oral dosing of DZD1516 in combination with T-DM1 3.6 mg/kg intravenously (IV) once every 21 days

Locations

Country	Name	City	State
China	Zhejiang Cancer Hospital	Hangzhou
China	Cancer Hospital, Fudan University	Shanghai
United States	UCLA Hematology/Oncology Parkside	Santa Monica	California

Sponsors (1)

Lead Sponsor	Collaborator
Dizal Pharmaceuticals

Countries where clinical trial is conducted

United States,  China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of adverse events (AEs) and serious adverse events (SAEs)	To investigate the safety and tolerability of DZD1516	up to approximately 1 year
Primary	Incidence of dose limiting toxicities (DLTs)	To investigate the safety and tolerability of DZD1516	21 days after the first multiple dose
Primary	To define maximum tolerated dose (MTD) of DZD1516 if possible (Part A only)	To investigate the safety and tolerability of DZD1516	21 days after the first multiple dose
Primary	To define Recommended Phase II Combination Dose (RP2CD) of DZD1516 in combination with trastuzumab and capecitabine (Part B only)	To investigate the safety and tolerability of DZD1516 in combination with either trastuzumab, capecitabine, or both trastuzumab and capecitabine	21 days after the first multiple dose
Primary	To define Recommended Phase II Combination Dose (RP2CD) of DZD1516 in combination with T-DM1 (Part C only)	To investigate the safety and tolerability of DZD1516 in combination with T-DM1	21 days after the first multiple dose
Secondary	Drug concentrations of DZD1516 and its metabolite DZ2678 in plasma, urine and CSF	Pharmacokinetics endpoints	up to approximately 6 months
Secondary	Maximum plasma concentration (Cmax) of DZD1516 and its metabolite DZ2678	Pharmacokinetics endpoints	up to approximately 6 months
Secondary	Area under the plasma concentration-time curve (AUC) of DZD1516 and its metabolite DZ2678	Pharmacokinetics endpoints	up to approximately 6 months
Secondary	Plasma concentration of capecitabine and metabolites 5-FU (Part B only)	Pharmacokinetics endpoints	up to approximately 6 months
Secondary	Plasma Cmax of capecitabine and 5-FU (Part B only)	Pharmacokinetics endpoints	up to approximately 6 months
Secondary	Plasma AUC of capecitabine and 5-FU (Part B only)	Pharmacokinetics endpoints	up to approximately 6 months
Secondary	Plasma concentration of DM1 (Part C only)	Pharmacokinetics endpoints	up to approximately 6 months
Secondary	Objective Response Rate (ORR)	To assess preliminary anti-tumor efficacy of DZD1516 as monotherapy and as combination therapy	up to approximately 1 year
Secondary	Disease Control Rate (DCR)	To assess preliminary anti-tumor efficacy of DZD1516 as monotherapy and as combination therapy	up to approximately 1 year
Secondary	Duration of Response (DoR)	To assess preliminary anti-tumor efficacy of DZD1516 as monotherapy and as combination therapy	up to approximately 1 year
Secondary	Progression free survival (PFS) (Part B and Part C on)	To assess preliminary anti-tumor efficacy of DZD1516 as combination therapy	up to approximately 1 year
Secondary	Overall survival (for patients with leptomeningeal metastasis in Part B and Part C only)	To assess preliminary anti-tumor efficacy of DZD1516 as combination therapy	up to approximately 1 year